1 Min Read
Dec 19 (Reuters) - Regulus Therapeutics Inc:
* REGULUS ANNOUNCES FIRST-IN-HUMAN DOSING FOR PHASE I STUDY OF RGLS4326 FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.